A Study of the Comparative Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in Japan (RePhlect)

Sponsor
Bristol-Myers Squibb
Study ID
NCT06382987
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Deucravacitinib — DRUG
    According to the product label
  • Apremilast — DRUG
    According to the product label

Study Details

This is a prospective, observational, real-world study of adult participants in Japan with physician-reported diagnosis of plaque psoriasis treated with deucravacitinib or apremilast.

Key Dates

Start date
Jan 22, 2024
Status verified
Apr 2024
Primary completion
Dec 31, 2029
Completion
Dec 31, 2029

Study Design

Enrollment
600 participants (estimated)

Arms

  • Arm: Participants that have initiated deucravacitinib treatment
  • Arm: Participants that have initiated apremilast treatment

Primary Outcome Measure

Change in percent Body Surface Area (BSA) involved affected by plaque psoriasis from baseline to follow up in participants treated with deucravacitinib. [ Time Frame: 1 month, 3 months, 6 months and every 6 months up to 5 years ]

Central Contacts

  • BMS Study Connect Contact Center www.BMSStudyConnect.com
    855-907-3286
    [email protected]
  • First line of the email MUST contain NCT # and Site #.

Related Studies